Jefferies Financial Group Inc. Purchases Shares of 2,963 Axon Enterprise, Inc $AXON

Jefferies Financial Group Inc. purchased a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) during the 3rd quarter, HoldingsChannel reports. The fund purchased 2,963 shares of the biotechnology company’s stock, valued at approximately $2,126,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of AXON. Newbridge Financial Services Group Inc. lifted its holdings in shares of Axon Enterprise by 2.8% in the second quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after buying an additional 14 shares during the period. Vicus Capital grew its holdings in Axon Enterprise by 3.7% during the third quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 14 shares during the period. Evergreen Capital Management LLC raised its position in Axon Enterprise by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after acquiring an additional 15 shares in the last quarter. Blue Trust Inc. raised its position in Axon Enterprise by 2.5% in the third quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company’s stock worth $463,000 after acquiring an additional 16 shares in the last quarter. Finally, NorthCrest Asset Manangement LLC lifted its holdings in Axon Enterprise by 5.4% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 16 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Recent operating momentum and scale: company commentary and filings highlighted robust device and software demand, rising ARR/bookings and accelerating revenue that underpinned the prior rally. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Positive Sentiment: Analyst backing and price-target runway: multiple firms maintain buy/overweight ratings and the median 6‑month target sits well above current levels, giving upside for longer-term holders. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Positive Sentiment: Momentum recap: AXON had climbed nearly 29% over the prior month on strong device/software demand — a factor that supports the bull case if execution continues. Axon Stock Rises 28.6% in a Month: Should Investors Buy or Wait?
• Neutral Sentiment: No meaningful short-interest signal (data shows zero or NaN) — likely a reporting anomaly, so it shouldn’t be interpreted as a fresh bearish catalyst.
• Neutral Sentiment: Third‑party/industry headlines referencing “Axon” (e.g., AppLovin’s “Axon by AppLovin” product and related studies) are unrelated to Axon Enterprise’s business and can confuse coverage — treat those items as industry noise. AppLovin (APP) Is Up 19.5% After Showcasing AXON 2.0 And AI E-commerce Pivot
• Negative Sentiment: Profit‑taking and valuation sensitivity: analysts and market commentary point to a classic post‑earnings retracement after a fast run; high valuation metrics make the stock susceptible to short‑term pullbacks. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Negative Sentiment: Heavy insider selling noted in recent disclosures increases near‑term perceived risk and can sap sentiment even if proceeds are routine. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Negative Sentiment: Relative underperformance vs. peers on the day added selling pressure, suggesting short‑term rotation rather than a fresh fundamental shift. Axon Enterprise Inc. stock underperforms Tuesday when compared to competitors

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on AXON shares. Morgan Stanley reduced their price objective on shares of Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Needham & Company LLC dropped their target price on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Wall Street Zen raised shares of Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Royal Bank Of Canada reduced their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a report on Wednesday, February 25th. Finally, William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, February 3rd. Sixteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $762.93.

Insider Activity

In related news, insider Isaiah Fields sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the transaction, the insider directly owned 55,588 shares of the company’s stock, valued at approximately $29,740,135.88. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the transaction, the chief executive officer directly owned 3,090,997 shares in the company, valued at $1,546,240,339.28. The trade was a 0.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 24,634 shares of company stock worth $13,803,095 in the last 90 days. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $517.57 on Thursday. Axon Enterprise, Inc has a 1-year low of $396.41 and a 1-year high of $885.91. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $41.61 billion, a price-to-earnings ratio of 340.51, a P/E/G ratio of 11.31 and a beta of 1.46. The stock’s fifty day simple moving average is $533.80 and its 200-day simple moving average is $613.08.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.55. The business had revenue of $796.72 million for the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.Axon Enterprise’s revenue for the quarter was up 38.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.08 earnings per share. On average, sell-side analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.